Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$43.66

-0.88 (-1.98%)

, BBIO

BridgeBio

$20.89

-0.58 (-2.70%)

04:55
10/02/19
10/02
04:55
10/02/19
04:55

European Respiratory Society to hold a conference

ERS International Congress 2019 will be held in Madrid, Spain on September 28-October 2.

AZN

AstraZeneca

$43.66

-0.88 (-1.98%)

BBIO

BridgeBio

$20.89

-0.58 (-2.70%)

BDX

Becton Dickinson

$250.70

-2.3 (-0.91%)

BLPH

Bellerophon

$0.50

-0.0119 (-2.33%)

BMXMF

bioMerieux

$0.00

(0.00%)

BSX

Boston Scientific

$40.24

-0.46 (-1.13%)

FGEN

FibroGen

$36.22

-0.73 (-1.98%)

FUJIY

Fujifilm

$0.00

(0.00%)

GLPG

Galapagos

$146.45

-6.35 (-4.16%)

GSK

GlaxoSmithKline

$42.33

-0.365 (-0.86%)

INSM

Insmed

$17.20

-0.46 (-2.60%)

LIN

Linde plc

$188.56

-5.04 (-2.60%)

NVS

Novartis

$85.98

-0.97 (-1.12%)

OXFD

Oxford Immunotec

$15.90

-0.62 (-3.75%)

PHG

Philips

$45.16

-0.97 (-2.10%)

PIRS

Pieris Pharmaceuticals

$3.16

-0.245 (-7.20%)

PKI

PerkinElmer

$83.51

-1.615 (-1.90%)

RMD

ResMed

$133.54

-1.625 (-1.20%)

SNY

Sanofi

$45.17

-1.18 (-2.55%)

  • 02

    Oct

  • 02

    Oct

  • 15

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 23

    Oct

  • 25

    Oct

  • 31

    Oct

  • 31

    Oct

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

AZN AstraZeneca
$43.66

-0.88 (-1.98%)

09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/03/19
DZBN
09/03/19
DOWNGRADE
DZBN
Sell
AstraZeneca downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Elmar Kraus downgraded AstraZeneca to Sell from Hold with a price target of 66 pounds.
08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Competitor PARP data an incremental negative for Clovis, says JPMorgan
JPMorgan analyst Cory Kasimov said he views the Phase 3 data presented by AstraZeneca (AZN) and Merck (MRK) on their PARP inhibitor Lynparza in previously treated prostate cancer as incrementally negative to Clovis (CLVS), which has "a lot riding on the prostate indication" since its Rubraca is "neck-and-neck with the competition to be first to market." While there wasn't anything bad reported at the ESMO meeting from Clovis' own prostate update, AstraZeneca "looks primed to come to market with a much more robust data set" and Clovis may "be playing catch-up" in another cancer indication, said Kasimov, who keeps a Neutral rating on Clovis shares.
BBIO BridgeBio
$20.89

-0.58 (-2.70%)

07/26/19
07/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dentsply Sirona (XRAY) initiated with an In Line at Evercore ISI. 2. BridgeBio (BBIO) initiated with an Outperform at Raymond James. 3. Crispr Therapeutics (CRSP) initiated with a Buy at Canaccord. 4. GeoPark (GPRK) initiated with a Buy at GMP Securities. 5. Neon Therapeutics (NTGN), Gritstone Oncology (GRTS), and Cue Biopharma (CUE) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/19
BTIG
09/13/19
NO CHANGE
Target $56
BTIG
Buy
Eidos Therapeutics price target raised to $56 from $38 at BTIG
BTIG analyst Thomas Shrader raised his price target on Eidos Therapeutics (EIDX) to $56 and kept his Buy rating after the decision by its board to reject an acquisition offer from parent company BridgeBio (BBIO) to buy all of its outstanding stock. The analyst notes that he always believed the combined entity would not be a more attractive investment, saying he is positive on the company's "declaration of independence". Shrader further cites the added revenue contribution expected from Eidos Therapeutics' deal with Alexion (ALXN) to develop and commercialize AG10 in Japan.
07/26/19
RAJA
07/26/19
INITIATION
Target $36
RAJA
Outperform
BridgeBio initiated with an Outperform at Raymond James
Raymond James analyst Dane Leone initiated BridgeBio with an Outperform and $36 price target.
07/26/19
RAJA
07/26/19
INITIATION
Target $36
RAJA
Outperform
Raymond James starts BridgeBio at Outperform with $36 price target
As previously reported, Raymond James analyst Dane Leone initiated BridgeBio with an Outperform rating and $36 price target. His Outperform rating is mostly predicated upon the company's key programs for TTR amyloidosis, cholangiocarcinoma and urothelial carcinoma and achondroplasia, Leone stated, adding that the company is unique in the way its project management team incentive compensation is aligned with the outcomes of the specific drugs they are working on.
BDX Becton Dickinson
$250.70

-2.3 (-0.91%)

05/13/19
05/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/19
ARGS
06/21/19
NO CHANGE
Target $290
ARGS
Buy
FDA advisory committee review of Becton Dickinson's DCB's a positive, says Argus
Argus analyst David Toung kept his Buy rating and $290 price target on Becton Dickinson, saying the recommendation by the FDA advisory committee that the company performs additional evaluation of the long-term safety of its drug-coated balloons, or DCBs, is a "positive" for the stock. The analyst states that the committee "notably" highlighted the benefit of the balloons and did not recommend that the product is removed from the market. Toung adds that as Becton Dickinson progresses with its acquisition of C.R. Bard, it is "delivering" on revenue growth, margin expansion, and revenue synergies, even though the regulatory advisory from the FDA has lowered his assumed FY19 and FY20 EPS view by 45c and 25c to $11.75 and $13.15 respectively.
09/26/19
WELS
09/26/19
NO CHANGE
WELS
Outperform
Becton Dickinson CEO transition not surprising, timing makes sense, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that Becton Dickinson announced that current chairman and CEO Vince Forlenza will retire as CEO on January 1st, 2020 and that Tom Polen, current president and COO, will step into the role CEO and President. The analyst says the news does not come as a surprise based on management commentary over the past year, his tenure at Becton Dickinson and his age. The timing of the transition makes sense as the company enters the last year of BCR integration and is looking at the next phase of growth in 2021 and beyond, he contends. Overall, Biegelsen does not expect any material changes to Becton Dickinson's outlook or strategic direction under Polen's leadership. The analyst has an Outperform rating on the shares.
08/06/19
PIPR
08/06/19
NO CHANGE
PIPR
Becton Dickinson price target lowered to $266 from $267 at Piper Jaffray
Piper Jaffray analyst William Quirk maintained an Overweight rating on Becton Dickinson, but lowered his price target on shares to $266 from $267, following the company's Q3 earnings results. Quirk said the quarter, which beat on EPS and missed slightly on revenue, with management reiterating FY19 guidance, was "good, not great." The analyst also noted that Becton Dickinson is accelerating the growth curve in the second half of the year, which he called a "positive indicator."
BLPH Bellerophon
$0.50

-0.0119 (-2.33%)

01/24/19
MAXM
01/24/19
INITIATION
MAXM
Buy
Bellerophon initiated with a Buy at Maxim
01/24/19
MAXM
01/24/19
INITIATION
Target $3
MAXM
Buy
Bellerophon initiated with a Buy at Maxim
Maxim analyst Caroline Palomeque initiated Bellerophon with a Buy rating and a price target of $3, saying the company's lead product INOpulse is well positioned in the absence of other "FDA-approved treatment options for pulmonary hypertension associated with Interstitial Lung Disease". The analyst notes that shares were down significantly in Q3 of 2018 after the company's phase 3 study in pulmonary arterial hypertension was stopped for futility, but she sees upside from the program's intact clinical path forward and expectations of more data later this year.
BMXMF bioMerieux
$0.00

(0.00%)

BSX Boston Scientific
$40.24

-0.46 (-1.13%)

09/20/19
COWN
09/20/19
NO CHANGE
Target $47
COWN
Outperform
Boston Scientific setting up well for better second half, says Cowen
Cowen analyst Joshua Jennings said Boston Scientific is setting up for a batter second half to the year as the company has a steady flow of product launches scheduled for the second half and should also experience momentum in its core businesses over that interval. In addition, there is one more selling day in the second half versus one less in the first. Jennings reiterated his Outperform rating and $47 price target on Boston Scientific shares.
09/03/19
LEHM
09/03/19
INITIATION
Target $48
LEHM
Overweight
Boston Scientific reinstated with an Overweight at Barclays
Barclays analyst Kristen Stewart reinstated coverage of Boston Scientific with an Overweight rating and $48 price target. With multiple new products across all of its business units, the company is well positioned to sustain high-single digit organic sales growth for the foreseeable future, Stewart tells investors in a research note. She believes the consensus view on the stock "is the right view."
09/05/19
09/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with an Equal Weight at Morgan Stanley. 2. Organigram (OGI) initiated with a Perform at Oppenheimer. 3. Wingstop (WING) initiated with a Market Perform at Raymond James. 4. Boston Scientific (BSX) reinstated with an Overweight at JPMorgan. 5. Cubic (CUB) initiated with a Hold at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/19
JPMS
09/05/19
INITIATION
Target $50
JPMS
Overweight
Boston Scientific reinstated with an Overweight at JPMorgan
JPMorgan analyst Robbie Marcus reinstated coverage of Boston Scientific with an Overweight rating and $50 price target following a period of restriction. The analyst continues to see the company as a "best-in-class Large-Cap MedTech asset," with "many shots on goal" to support a multi-year premium organic sales growth trajectory of 7%-10% through 2023.
FGEN FibroGen
$36.22

-0.73 (-1.98%)

06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper says buy Akebia before market figures out competitive positoin
After hosting an investor call with Akebia Therapeutics (AKBA) CEO John Butler, Piper Jaffray analyst Christopher Raymond thinks vadadustat's competitive position relative to FibroGen's (FGEN) roxadustat is "stronger, not weaker now." As such, the analyst recommends buying shares of Akebia "before the market begins to figure this out." Raymond left the call incrementally confident in vadadustat "on a number of levels," namely its approvability given Akebia's alignment with FDA on trial design and statistical analysis. He keeps an Overweight rating on the shares with a $22 price target.
05/29/19
GSCO
05/29/19
INITIATION
Target $45
GSCO
Neutral
FibroGen assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi assumed coverage of FibroGen with a Neutral rating and $45 price target. Prior analyst Terence Flynn had a Neutral rating on the shares with a $56 price target. Following the recent Phase 3 MACE safety results for roxadustat, the analyst sees the shares as range-bound pending further clarity from the FDA.
06/10/19
JEFF
06/10/19
NO CHANGE
Target $75
JEFF
Buy
FibroGen shares may rebound with FDA meeting feedback, says Jefferies
Jefferies analyst Michael Yee says his recent meeting with FibroGen management suggested the company's progress is well on track, with the FDA meeting soon. There could be more disclosure with an FDA agreement soon and a new drug application filing on time in Q3, which "should calm the Street," Yee tells investors in a research note. The analyst thinks the post-FDA meeting disclosure, confirmation of filing, and potentially more detailed data from Phase III could cause shares of FibroGen to rebound.
07/24/19
HCWC
07/24/19
NO CHANGE
Target $19
HCWC
Buy
Akebia shares at 'excellent entry point,' says H.C. Wainwright
After Akebia (AKBA) announced that its Japanese partner on vadadustat has submitted a New Drug Application in Japan that supports approval for anemia due to chronic kidney disease in both non-dialysis and dialysis patients, H.C. Wainwright analyst Ed Arce noted that this represents the first regulatory submission for vadadustat. The current valuation, with shares trading near 52-week lows, presents "an excellent entry point" given that the primary bear thesis depends on the first-to-market advantage of Fibrogen's (FGEN) roxadustat, which Arce views as "fundamentally flawed," he tells investors. In light of the JNDA submission, as well as the current timeline, Arce pushed back his U.S. and EU market launch and initial sales estimates to early 2022 and trimmed his price target on Akebia shares to $19 from $21, but he keeps a Buy rating on the stock.
FUJIY Fujifilm
$0.00

(0.00%)

GLPG Galapagos
$146.45

-6.35 (-4.16%)

09/09/19
MSCO
09/09/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos with an Overweight rating and $200 price target.
09/10/19
MSCO
09/10/19
INITIATION
Target $200
MSCO
Overweight
Galapagos resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Galapagos (GLPG) with an Overweight rating and $200 price target. The analyst believes Galapagos is well positioned for success following the transaction with Gilead (GILD). He believes Gilead offers a "strong partner" to drive the company's "broad" pipeline while building commercial operations in Europe. Filgotinib will drive near-term upside in Galapagos shares while its greater than $5B cash position provides downside protection, Harrison tells investors in a research note.
07/29/19
RBCM
07/29/19
NO CHANGE
Target $171
RBCM
Sector Perform
Galapagos price target raised to $171 from $132 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Galapagos (GLPG) to $171, saying the company is in a "comfortable position" after its "lucrative" Gilead (GILD) deal and the elevation of Filgotinib to commercial status possibly coming next year. The analyst cites the FDA's greater permissiveness on filing and the company's latest comments on Filgotinib safety, though he also intends to monitor the "competitive dynamics" to gauge the program's long-term potential.
07/31/19
UBSW
07/31/19
UPGRADE
UBSW
Buy
Galapagos upgraded to Buy from Neutral at UBS
GSK GlaxoSmithKline
$42.33

-0.365 (-0.86%)

09/03/19
SOCG
09/03/19
UPGRADE
SOCG
Buy
GlaxoSmithKline upgraded to Buy from Sell at Societe Generale
09/03/19
SOCG
09/03/19
UPGRADE
SOCG
Buy
Societe Generale double upgrades GlaxoSmithKline to Buy
As previously reported, Societe Generale analyst Justin Smith upgraded GlaxoSmithKline to Buy from Sell in a research note titled 'An intriguing metamorphosis.' The analyst said he waited to upgrade the stock, despite liking "all the management and capital allocation changes" that new CEO Emma Walmsley has made in her first two years in charge, because he wanted to see "clear evidence of improving innovation" with GlaxoSmithKline's Pharma business. Smith now sees five high profile assets in Phase 3 that will release results in the next 3-4 years, giving improved pipeline visibility, and leaving the analyst forecasting "above-average sales growth from 2023."
08/13/19
JPMS
08/13/19
INITIATION
JPMS
Neutral
GlaxoSmithKline reinstated with a Neutral at JPMorgan
JPMorgan analyst James Gordon reinstated coverage of GlaxoSmithKline with a Neutral rating and 1,700p price target. The analyst sees the stock near-term being Brexit and currency moves.
09/04/19
COWN
09/04/19
NO CHANGE
Target $48
COWN
Outperform
Pfizer shares remain attractively valued, says Cowen
Cowen analyst Steve Scalia updated his Pfizer (PFE) model following Q2 results, the closing of the Glaxo (GSK) Consumer joint venture, and the announcement that its Upjohn business would be divested and combined with Mylan (MYL). The analyst lowered his estimates to reflect what is left at the company and despite his revision feels the shares remain attractively valued. Scalia reiterated his Outperform rating and $48 price target on Pfizer shares.
INSM Insmed
$17.20

-0.46 (-2.60%)

04/09/19
HCWC
04/09/19
NO CHANGE
Target $52
HCWC
Buy
Insmed price target raised to $52 from $43 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Insmed to $52 from $43 saying the company yesterday announced a positive update on the U.S. launch of Arikayce. The broadening of the prescriber base "is not short lived and can continue, as well as possibly be supplemented by label expansion into first line patients," Fein tells investors in a research note. He keeps a Buy rating on the shares.
03/26/19
STFL
03/26/19
NO CHANGE
Target $43
STFL
Buy
Pulmonologist call reinforces Stifel view of upside for Insmed
After hosting a conference call with two key opinion leader pulmonologists to discuss the rollout of Arikayce, Stifel analyst Adam Walsh said their feedback suggested the strong start for the drug was not the result of a "bolus" of patients awaiting approval and noted that both doctors said their new-patient starts remain steady. While it "remains early days in the launch," the call with the doctors reinforced his belief that Insmed's Arikayce guidance is likely conservative, Walsh tells investors. He keeps a Buy rating and $43 price target on Insmed shares.
08/01/19
STFL
08/01/19
NO CHANGE
Target $43
STFL
Buy
Insmed selloff 'decidedly overdone,' says Stifel
Stifel analyst Adam Walsh notes that despite another "strong beat and raise quarter," Insmed's shares are trading off, which is likely attributable to persistent concerns regarding future Arikayce drop-outs leading to a flattening of the growth curve, some timing uncertainty on the front-line trial launch, and the recent capital raise done at $26/share and related selling pressure based on that alone. On drop-outs, the analyst acknowledges lack of long-term visibility but believes the rate thus far has been better than expected. On the PRO measure, Walsh believes it is "critically important" for Insmed to "get it right," given the large font-line opportunity. Overall, the analyst sees the selloff as "decidedly overdone" in light of the continued strong Arikayce launch execution and encouraging forward guidance. Walsh reiterates a Buy rating and $43 price target on the shares.
09/03/19
GSCO
09/03/19
INITIATION
Target $30
GSCO
Buy
Insmed initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh initiated Insmed with a Buy rating and a price target of $30, saying the stock offers an attractive entry point at 50% below its 52-week high as a de-risked commercial-stage biopharma with "significant" potential for expansion. The analyst contends that Insmed's lead orphan lung disease product Arikayce is well-positioned with it's early life cycle stage, no obvious competition and the potential for both geographic and label expansion. Suvannavejh adds that the company's INS1007 also has pipeline potential while garnering "little investor attention".
LIN Linde plc
$188.56

-5.04 (-2.60%)

07/09/19
KEYB
07/09/19
NO CHANGE
Target $220
KEYB
Overweight
Linde plc price target raised to $220 from $205 at KeyBanc
KeyBanc analyst Michael Sison raised his price target for Linde plc to $220 from $205 as he expects growth will be driven by integration synergy, pricing, and new project growth. In addition, the Industrial Gases offer good balance of defensive features with long-term contracts, he contends. The analyst reiterates an Overweight rating on the shares.
07/12/19
SBSH
07/12/19
DOWNGRADE
SBSH
Neutral
Chemours downgraded to Neutral from Buy at Citi
Citi analyst P.J. Juvekar downgraded Chemours (CC) to Neutral from Buy saying he's turned more cautious on ethylene and TiO2. With three new ethylene crackers in the second half of 2019 and falling raw materials, the risk to polyethylene prices is to the downside, Juvekar tells investors in a research note. He prefers "more defensive names with strong balance sheets," such as Linde plc (LIN), Sherwin-Williams (SHW) and Nutrien (NTR).
08/06/19
DBAB
08/06/19
NO CHANGE
Target $215
DBAB
Buy
Linde plc price target raised to $215 from $205 at Deutsche Bank
Deutsche Bank analyst David Begleiter raised his price target for Linde plc to $215 from $205 following the company's "solid" Q2 results. The analyst expects Linde plc to formally raise its 2019 synergy target of $225M and its total synergy target of $900M at the Q3 earnings release. He keeps a Buy rating on the shares.
08/28/19
LEHM
08/28/19
NO CHANGE
Target $5
LEHM
Equal Weight
Mallinckrodt patent ruling 'clearly a setback,' says Barclays
Barclays analyst Balaji Prasad says the appeals court ruling yesterday that Linde's (LIN) Praxair did not infringe INOmax patents is "clearly a setback" for Mallinckrodt (MNK). The analyst, who points out that he had already factored in declining INOmax growth on a risk adjusted basis, says Praxair's launch strategy will now influence the pace of deceleration in INOmax revenues. Offsetting factors for Mallinckrodt will likely be the value in label expansions and its next generation INOmax EVOLVE system "that could be a growth driver," with potential approval and launch in the second half of 2020, Prasad tells investors in a research note. The analyst keeps an Equal Weight rating on Mallinckrodt shares with a $5 price target.
NVS Novartis
$85.98

-0.97 (-1.12%)

08/13/19
OPCO
08/13/19
NO CHANGE
Target $230
OPCO
Outperform
Amgen price target raised to $230 from $210 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.
08/12/19
LEHM
08/12/19
NO CHANGE
Target $31
LEHM
Overweight
Coherus should be bought on weakness from Enbrel ruling, says Barclays
Barclays analyst Balaji Prasad recommends buying shares of Coherus Biosciences (CHRS) on any weakness from Amgen's (AMGN) favorable Enbrel patent ruling against Novartis (NVS). Coherus is developing its own Enbrel generic, says the analyst, whose model already factors a launch in Q2 of 2029, following the expiration of the last U.S. Enbrel patent. As such, Prasad is making no change to his estimates following Friday's decision. He remains positive on Coherus and would use any share weakness as an opportunity to add a "fundamentally sound company." Prasad reiterates an Overweight rating on the shares with a $31 price target.
09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.
OXFD Oxford Immunotec
$15.90

-0.62 (-3.75%)

03/12/19
BARD
03/12/19
NO CHANGE
Target $19
BARD
Outperform
Oxford Immunotec's 2019 guidance seems 'conservative,' says Baird
Baird analyst Catherine Ramsey Schulte says Oxford Immunotec reported a "solid" Q4 on Monday, with double-digit TB growth across all major geographies. In a research note to investors, the analyst says she thinks 2019 guidance seems conservative and believes double-digit TB growth should be doable, but notes that she does not expect a meaningful revenue inflection from the Quest deal until 2020 and beyond. She maintains an Outperform rating on the shares with a $19 price target.
09/18/19
PIPR
09/18/19
NO CHANGE
Target $20
PIPR
Overweight
Oxford Immunotec's new approach to China could boost sales, says Piper Jaffray
Oxford Immunotec Global announced last night that it terminated its distributor agreements in China due to unacceptable performance, Piper Jaffray analyst William Quirk tells investors in a research note. As an alternative, the analyst believes Oxford will use a combination of direct selling and distribution for the Chinese market. This new approach should improve the company's overall revenue as it no longer has to pay transfer prices to distributors, but at the same time will likely lead to increased operating expenses, says Quirk. Importantly, Oxford's former distributor will be prohibited from selling latent TB tests in China, per their agreement, the analyst adds. He keeps an Overweight rating on Oxford Immunotec shares with a $20 price target.
03/12/19
PIPR
03/12/19
NO CHANGE
Target $20
PIPR
Overweight
Oxford Immunotec well positioned for strong 2019 transition, says Piper Jaffray
Piper Jaffray analyst William Quirk says Oxford Immunotec last night reported a "solid" quarter, with pro-forma revenue above consensus, earnings in-line and guidance above consensus. With "incremental visibility" into the new business model, the analyst is confident the company is setting itself up well for a strong transition in 2019. He reiterates an Overweight rating on the shares with a $20 price target.
09/24/19
COWN
09/24/19
NO CHANGE
Target $20
COWN
Outperform
Oxford Immunotec company sale may make sense, says Cowen
Cowen analyst Doug Schenkel noted reports Oxford Immunotec is exploring a sale after attracting acquisition interest. The analyst thinks a potential sale may make sense, especially at the current juncture as there a number of factors working in favor of a sale including its cash balance and growth outlook. He believes if a sale happens it would occur in the $20-$25 range. Schenkel reiterated his Outperform rating and $20 price target on Oxford Immunotec shares.
PHG Philips
$45.16

-0.97 (-2.10%)

07/30/19
SBSH
07/30/19
INITIATION
SBSH
Buy
Philips initiated with a Buy at Citi
Citi analyst Kate Kalashnikova started Philips with a Buy rating and 49 euros price target. The expects the company's earnings momentum in diagnosis and treatment to continue as well as its recovery in personal health.
07/30/19
07/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tencent Music (TME) initiated with an Outperform at Oppenheimer. 2. Medallia (MDLA) initiated with an Overweight at Stephens. 3. Fanhua (FANH) initiated with an Overweight at Morgan Stanley. 4. Philips (PHG) initiated with a Buy at Citi. 5. Freshpet (FRPT) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/18
DBAB
10/24/18
NO CHANGE
DBAB
Philips named a Catalyst Buy at Deutsche Bank
Deutsche Bank named Philips as a Catalyst Buy, stating that it expects investors to look past the temporary slowdown in Personal Health and focus on the much stronger than expected performance of Philips' Diagnosis & Treatment division.
04/16/19
BTIG
04/16/19
DOWNGRADE
BTIG
Neutral
Masimo downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Masimo (MASI) to Neutral mainly on valuation concerns, stating that while nothing has changed in his positive expectations for the company's performance, the stock may be "running out of steam". The analyst believes that Masimo should continue "taking market share, post strong revenue growth supported by multiple drivers, and enjoy adoption uplift through the Philips (PHG) co-marketing deal", but also sees the valuation on the stock reflecting "a good deal of the good news".
PIRS Pieris Pharmaceuticals
$3.16

-0.245 (-7.20%)

07/30/19
BARD
07/30/19
DOWNGRADE
Target $5
BARD
Neutral
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
Baird analyst Madhu Kumar downgraded Pieris Pharmaceuticals to Neutral from Outperform with an unchanged price target of $5.
07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.
05/14/19
BARD
05/14/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform rating and $5 price target, saying he believe's Pieris' anticalin platform has the potential to disrupt biologic therapies in the respiratory and oncology spaces. The analyst called out the company's Phase 1 single ascending dose results for anti-interleukin-4 receptor a Ac PRS060 as potentially validating the drug's utility in asthma and serve as a positive catalyst for shares.
05/13/19
BARD
05/13/19
INITIATION
Target $5
BARD
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Pieris Pharmaceuticals with an Outperform and $5 price target.
PKI PerkinElmer
$83.51

-1.615 (-1.90%)

05/30/19
WOLF
05/30/19
INITIATION
Target $97
WOLF
Peer Perform
PerkinElmer initiated with a Peer Perform at Wolfe Research
Wolfe Research started PerkinElmer with a Peer Perform rating and $97 price target.
04/09/19
04/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Market Perform at Cowen with analyst Doug Creutz saying he views Disney's "catalyst path for the next year as highly attractive" and believes Thursday's investor day will likely be a "deck-clearing event for sentiment." 2. Comcast (CMCSA) upgraded to Outperform from Neutral at Macquarie with analyst Amy Young saying she remains bullish on pure-play Altice and efforts across Sky, Xfinity, and NBCU. 3. Geron (GERN) upgraded to Buy from Hold at Needham with analyst Chad Messer saying the return of development rights for imetelstat in September by Janssen (JNJ) has created a "buying opportunity." 4. Public Storage (PSA) upgraded to Hold from Underperform at Jefferies with analyst Omotayo Okusanya saying with interest rates set to be lower for longer, equity risk premiums have dropped. 5. PerkinElmer (PKI) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Patrick Donnelly saying the continuation of the company's growth acceleration should exceed "conservative" expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/19
BOFA
09/26/19
UPGRADE
BOFA
Buy
PerkinElmer upgraded to Buy from Neutral at BofA/Merrill
09/26/19
BOFA
09/26/19
UPGRADE
BOFA
Buy
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Bruker (BRKR), PerkinElmer (PKI), and Personalis (PSNL) to Buy from Neutral as part of his broader research note into Life Sciences & Diagnostic Tools. The analyst notes that the recent market volatility has sent many of the names in the sector "sharply lower", making their valuations more attractive. de Bruin is also positive on Bruker's new product portfolio and margin expansion opportunity. As part of the research note, the analyst cuts Myriad Genetics (MYGN) to Underperform from Neutral and lowers his price target on the shares to $28 from $30 after a bounce in its stock price and given his concern with its mixed execution.
RMD ResMed
$133.54

-1.625 (-1.20%)

07/29/19
GSCO
07/29/19
UPGRADE
GSCO
Buy
ResMed upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Chris Cooper upgraded ResMed to Buy from Neutral, citing his view that the current pricing dynamics are "more favorable than at any time through the last decade." He expects stable pricing across both Medicare and commercial channels through calendar 2020 and he expects ResMed to benefit from the breadth and depth of its portfolio, Cooper tells investors. The analyst, who now forecasts sales and EPS CAGRs of 8% and 11%, respectively, from FY19-22, raised his price target on ResMed shares to A$21.20 from A$16.70.
05/06/19
UBSW
05/06/19
UPGRADE
UBSW
Buy
ResMed upgraded to Buy from Neutral at UBS
07/16/19
UBSW
07/16/19
DOWNGRADE
UBSW
Neutral
ResMed downgraded to Neutral from Buy at UBS
05/03/19
05/03/19
DOWNGRADE

ResMed downgraded to Negative from Neutral at Evans & Partners
Evans & Partners analyst Steve Wheen downgraded ResMed to Negative from Neutral following the company's fiscal Q3 results. The analyst believes it is "time for the stock to take a breather on valuation grounds."
SNY Sanofi
$45.17

-1.18 (-2.55%)

09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy from Neutral at Guggenheim
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.
09/20/19
MSCO
09/20/19
UPGRADE
MSCO
Overweight
Morgan Stanley upgrades 'defensive' Sanofi to Overweight
As previously reported, Morgan Stanley upgraded Sanofi to Overweight from Equal Weight with analyst Mark Purcell arguing that the company has the lowest risk growth outlook in European pharma given its lack of major patent cliffs and the "largely de-risked" nature of pipeline drugs in the late stages. He thinks Sanofi's defensive qualities position it as a key holding in the current environment and also believes the company's new CEO Paul Hudson has significant optionality to unlock shareholder value, Purcell tells investors. He raised his price target on Sanofi shares to EUR90 from EUR79.

TODAY'S FREE FLY STORIES

ESYJY

easyJet

$0.00

(0.00%)

20:35
11/19/19
11/19
20:35
11/19/19
20:35
Initiation
easyJet initiated at Goldman Sachs »

easyJet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSEX

Middlesex Water

$62.07

1.5 (2.48%)

20:31
11/19/19
11/19
20:31
11/19/19
20:31
Syndicate
Middlesex Water 661K share Spot Secondary priced at $60.50 »

Baird is acting as lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

DLAKY

Lufthansa

$0.00

(0.00%)

20:29
11/19/19
11/19
20:29
11/19/19
20:29
Initiation
Lufthansa initiated at Goldman Sachs »

Lufthansa initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

, LOW

Lowe's

$113.41

-1.62 (-1.41%)

20:25
11/19/19
11/19
20:25
11/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$110.86

0.27 (0.24%)

LOW

Lowe's

$113.41

-1.62 (-1.41%)

NTES

NetEase

$288.77

-1.33 (-0.46%)

CPRT

Copart

$86.33

0.32 (0.37%)

LB

L Brands

$17.19

-0.67 (-3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

ICAGY

IAG

$0.00

(0.00%)

20:23
11/19/19
11/19
20:23
11/19/19
20:23
Initiation
IAG initiated at Goldman Sachs »

IAG initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYAAY

Ryanair

$86.27

0.52 (0.61%)

20:20
11/19/19
11/19
20:20
11/19/19
20:20
Initiation
Ryanair initiated at Goldman Sachs »

Ryanair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXFR

Luxfer

$17.57

0.16 (0.92%)

20:11
11/19/19
11/19
20:11
11/19/19
20:11
Initiation
Luxfer initiated at B. Riley FBR »

Luxfer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAL

Valaris

$3.69

-0.515 (-12.26%)

20:09
11/19/19
11/19
20:09
11/19/19
20:09
Initiation
Valaris initiated at Deutsche Bank »

Valaris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$4.66

-0.16 (-3.32%)

20:03
11/19/19
11/19
20:03
11/19/19
20:03
Initiation
Transocean initiated at Deutsche Bank »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$19.29

-0.24 (-1.23%)

19:58
11/19/19
11/19
19:58
11/19/19
19:58
Initiation
TechnipFMC initiated at Deutsche Bank »

TechnipFMC initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$34.31

-0.36 (-1.04%)

19:53
11/19/19
11/19
19:53
11/19/19
19:53
Initiation
Schlumberger initiated at Deutsche Bank »

Schlumberger initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTEN

Patterson-UTI

$8.49

-0.095 (-1.11%)

19:45
11/19/19
11/19
19:45
11/19/19
19:45
Initiation
Patterson-UTI initiated at Deutsche Bank »

Patterson-UTI initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFE

Safehold

$34.59

-1.33 (-3.70%)

19:38
11/19/19
11/19
19:38
11/19/19
19:38
Syndicate
Safehold 3M share Secondary priced at $34.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 20

    Nov

HP

Helmerich & Payne

$38.39

-0.45 (-1.16%)

19:36
11/19/19
11/19
19:36
11/19/19
19:36
Initiation
Helmerich & Payne initiated at Deutsche Bank »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$19.89

-0.26 (-1.29%)

19:31
11/19/19
11/19
19:31
11/19/19
19:31
Initiation
Halliburton initiated at Deutsche Bank »

Halliburton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

BKR

Baker Hughes

$22.01

-0.155 (-0.70%)

19:24
11/19/19
11/19
19:24
11/19/19
19:24
Initiation
Baker Hughes initiated at Deutsche Bank »

Baker Hughes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHAT

Phathom Pharmaceuticals

$24.79

-0.09 (-0.36%)

19:23
11/19/19
11/19
19:23
11/19/19
19:23
Initiation
Phathom Pharmaceuticals initiated at Evercore ISI »

Phathom Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$584.48

-1.13 (-0.19%)

19:20
11/19/19
11/19
19:20
11/19/19
19:20
Downgrade
Sherwin-Williams rating change at Edward Jones »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$311.95

-0.06 (-0.02%)

, SPX

S&P 500

$0.00

(0.00%)

19:17
11/19/19
11/19
19:17
11/19/19
19:17
Periodicals
Commerce Sec Ross says China trade talks still work in progress, Bloomberg says »

U.S. Commerce Secretary…

SPY

SPDR S&P 500 ETF Trust

$311.95

-0.06 (-0.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

19:10
11/19/19
11/19
19:10
11/19/19
19:10
Downgrade
Berry Petroleum rating change at KeyBanc »

Berry Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYMT

New York Mortgage

$6.25

0.015 (0.24%)

19:05
11/19/19
11/19
19:05
11/19/19
19:05
Syndicate
New York Mortgage 25M share Spot Secondary priced at $6.10 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LNG

Cheniere Energy

$59.77

-0.69 (-1.14%)

19:01
11/19/19
11/19
19:01
11/19/19
19:01
Hot Stocks
Cheniere Energy CEO buys 8.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

SQ

Square

$66.43

0.68 (1.03%)

18:57
11/19/19
11/19
18:57
11/19/19
18:57
Hot Stocks
Square CFO: Our mission is economic empowerment »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 10

    Dec

  • 26

    Feb

AVID

Avid Technology

$7.74

0.15 (1.98%)

, DL

China Distance Education

$7.15

0.05 (0.70%)

18:56
11/19/19
11/19
18:56
11/19/19
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Avid…

AVID

Avid Technology

$7.74

0.15 (1.98%)

DL

China Distance Education

$7.15

0.05 (0.70%)

ESE

Esco Technologies

$86.71

1.94 (2.29%)

BCRX

BioCryst

$2.03

0.33 (19.41%)

CTMX

CytomX Therapeutics

$5.15

-0.03 (-0.58%)

ENDP

Endo

$4.44

-0.02 (-0.45%)

AVYA

Avaya

$12.11

-0.22 (-1.78%)

BKR

Baker Hughes

$22.01

-0.155 (-0.70%)

URBN

Urban Outfitters

$28.73

-1.43 (-4.74%)

ALC

Alcon

$59.00

0.105 (0.18%)

ORGO

Organogenesis

$8.01

0.02 (0.25%)

AMRN

Amarin

$22.74

0.11 (0.49%)

CRSP

Crispr Therapeutics

$68.46

9.94 (16.99%)

MGP

MGM Growth

$32.46

-0.39 (-1.19%)

RIG

Transocean

$4.66

-0.16 (-3.32%)

NYMT

New York Mortgage

$6.25

0.015 (0.24%)

MSEX

Middlesex Water

$62.07

1.5 (2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 02

    Dec

  • 02

    Dec

  • 05

    Dec

  • 07

    Dec

  • 28

    Dec

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

NVDA

Nvidia

$207.90

-4.36 (-2.05%)

, MLNX

Mellanox

$114.40

0.245 (0.21%)

18:47
11/19/19
11/19
18:47
11/19/19
18:47
Hot Stocks
Nvidia CEO: We're at the beginning of the artificial intelligence revolution »

In an interview on…

NVDA

Nvidia

$207.90

-4.36 (-2.05%)

MLNX

Mellanox

$114.40

0.245 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 06

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.